



February 20, 2020

The Manager- Listing **BSE Limited** Corporate Relationship Dept., 5th Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai - 400001

The Manager- Listing **National Stock Exchange of India Limited** Exchange plaza, 5th Floor, Plot No. C/1, G Block Bandra –Kurla Complex, Bandra (E), Mumbai - 400051

Dear Sir(s),

Subject: Launch of FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets (QTERN®)

We refer to our communication dated September 25, 2019 intimating the receipt of Import and Market Permission in Form 45 (Marketing Authorization) from the Drugs Controller General of India for FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets (**QTERN**[®]).

With regard to the same, we now wish to further update that AstraZeneca Pharma India Limited has commenced the launch of **QTERN**[®] in India.

FDC of Dapagliflozin 10mg + Saxagliptin 5mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM).

We request you to kindly take the same on record.

For AstraZeneca Pharma India Limited

top Kindne

Pratap Rudra Company Secretary & Legal Counsel



CORPORATE & REGD. OFFICE AstraZeneca Pharma India Ltd. P. B. No. 4525, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore - 560 045, INDIA TEL : +91 80 6774 8000 FAX : +91 80 6774 8857 CIN : L24231KA1979PLC003563

WEB : www.astrazeneca.com/india

FACTORY 12th Mile on Bellary Road Venkatala, Kattigenahalli Village Yelahanka Bangalore - 560 063 INDIA

TEL : +91 80 6774 9000

FAX : +91 80 2846 2208 +91 80 6774 9628